Engineering an Artificial Myxopyronin Derivative with Enhanced Metabolic Stability via Mutasynthesis.

ABSTRACT: The rise of multidrug-resistant pathogens, such as Staphylococcus aureus and Mycobacterium tuberculosis, underscores an urgent need for therapeutic innovation. The antibiotic development pipeline targeting these bacteria is critically limited, with most discovered candidates exhibiting structurally similar features of prominent chemical entities and with well-established molecular targets or binding modes. The myxobacterial α-pyrone antibiotics, myxopyronins, represent a highly promising compound class due to their ability to inhibit RNA polymerase by binding to the "switch region", a distinct binding site to that of standard-of-care antibiotics. Mutasynthesis, leveraging engineered microorganisms and tailored precursors, provides a viable alternative to total synthesis for g

SUBMITTER: Kiefer AF 

PROVIDER: S-EPMC12728655 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature